Comment from Vasculitis Foundation

Summary: The Vasculitis Foundation, a patient-focused nonprofit, states that it does not take a definitive position on whether the FDA should proceed with the withdrawal of TAVNEOS. Instead, they urge the FDA to ensure the final benefit-risk determination fully incorporates patient perspectives, accounts for the risks of existing alternatives, and considers regulatory tools like updated labeling before deciding on withdrawal.